Document Detail


Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors.
MedLine Citation:
PMID:  18673224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Malaria is one of the most prevalent diseases of our planet which claims millions of lives annually. Plasmodium falciparum is the causative agent of majority of the mortality and morbidity associated with malaria particularly in tropical countries. Resistance of the parasite to the currently available chemotherapeutic agents poses a serious threat to human being. Inhibition of P. falciparum dihydrofolate reductase (DHFR) enzyme has been used as one of the strategies in curbing malaria. However, due to mutation in the active-site of the enzyme particularly at 16, 51, 59, 108, and 164 residues, the parasite developed resistance to most of antifolate drugs such as cycloguanil and pyrimethamine. Thus, design of new and potent antimalarial agents which are effective against both wild-type and mutant enzymes is very essential in order to minimize burden of P. falciparum malaria. Computer-aided drug design approaches are playing a crucial role in the design of potential antimalarial drug candidates. In this article, molecular modelling studies based on docking, pharmacophore mapping, QSAR, homology modelling, and quantum chemical studies are reviewed. The importance of these methods in understanding mechanism of drug resistance at a molecular level, and design of antimalarial drug candidates are discussed briefly. The examples mentioned in the review could give insights into the wide range of possibilities of using computer-aided drug design (CADD) methodologies.
Authors:
Legesse Adane; Prasad V Bharatam
Related Documents :
9625944 - Is halofantrine still advisable in malaria attacks?
6283344 - Inhibition of the in vitro growth of plasmodium falciparum by d vitamins and vitamin d-...
15119074 - Drug resistant falciparum malaria and the use of artesunate-based combinations: focus o...
7856824 - The diagnosis of plasmodium falciparum infection using a new antigen detection system.
11501334 - Contraindicated medications dispensed with cisapride: temporal trends in relation to th...
9688054 - Low swelling, crosslinked guar and its potential use as colon-specific drug carrier.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current medicinal chemistry     Volume:  15     ISSN:  0929-8673     ISO Abbreviation:  Curr. Med. Chem.     Publication Date:  2008  
Date Detail:
Created Date:  2008-08-04     Completed Date:  2008-09-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9440157     Medline TA:  Curr Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1552-69     Citation Subset:  IM    
Affiliation:
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar-160 062, Punjab, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antimalarials / chemistry*,  pharmacology*
Computational Biology
Folic Acid Antagonists / chemistry*,  pharmacology*
Humans
Models, Molecular
Plasmodium falciparum / drug effects*,  enzymology*
Tetrahydrofolate Dehydrogenase / chemistry,  metabolism*
Chemical
Reg. No./Substance:
0/Antimalarials; 0/Folic Acid Antagonists; EC 1.5.1.3/Tetrahydrofolate Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.
Next Document:  Structure -activity relationships of PDE5 inhibitors.